Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell
lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular …

Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …

For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable
molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L) 1 …

Background Inhibiting vascular endothelial growth factor (VEGF) function can improve the
efficacy of immunotherapy by modulating the tumor immune microenvironment. AK112 is the …

Lung cancer is the leading cause of cancer mortality worldwide. Immunotherapy has
demonstrated clinically significant benefit for non-small-cell lung cancer, but innate (primary) …

Lung cancer remains a leading cause of cancer death worldwide, with non-small-cell lung
cancer (NSCLC) accounting for the majority of cases. Immune checkpoint inhibitors (CPIs) …

The high primary resistance incidence and unavoidable secondary resistance are the major
clinical obstacle to lasting long-term benefits in Non-small-cell lung cancer (NSCLC) …

Purpose: Clinical patterns and the associated optimal management of acquired resistance to
PD-(L) 1 blockade are poorly understood. Experimental Design: All cases of metastatic lung …